ATNM_OUT_1 [2025-03-26 09:12:06 -0400] 2582 Bytes | 652 tokens | Cum: 652 tkns (8.15% of 8k)
==========================================================================

Listen up, partner—it's 9:12:05 AM on Wed Mar 26, 2025 -0400, and I’m revved up about Actinium Pharmaceuticals (ATNM), climbing from 1.58 to 1.95. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Actinium Pharmaceuticals:

C1 - Today 08:45AM - Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
C2 - Mar-25-25 06:00AM - Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
C3 - Mar-24-25 04:15PM - Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
C4 - Mar-20-25 08:00AM - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
C5 - Mar-19-25 08:30AM - Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
C6 - Mar-19-25 08:30AM 08:11AM - Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
C7 - Mar-18-25 08:00AM - Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO
C8 - Mar-17-25 08:50AM - Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Actinium Pharmaceuticals (ATNM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ATNM_OUT_3 [2025-03-26 09:12:08 -0400] 1039 Bytes | 257 tokens | Cum: 911 tkns (11.39% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today**
Date: Today 08:45AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-business-update-at-trump-mar-a-lago-club-today-302411734.html

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure

- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities inmyeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical dataexpected in 2025 supporting each addressable market

- Presentation follows Investor KOL Event and Company Update onMarch 25th

NEW YORK,March 26, 2025/PRNewswire/ --Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_5 [2025-03-26 09:12:12 -0400] 1012 Bytes | 277 tokens | Cum: 1190 tkns (14.88% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T20:47:13Z - Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to...
A2 - 2025-03-24T20:24:57Z - Actinium secures Ac-225 supply for cancer therapy trials By Investing.com...
A3 - 2025-03-24T20:21:25Z - Actinium Pharma (ATNM) Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to S...
A4 - 2025-03-20T13:21:16Z - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support F...
A5 - 2025-03-20T12:01:02Z - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support F...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ATNM_OUT_7 [2025-03-26 09:12:13 -0400] 1038 Bytes | 295 tokens | Cum: 1487 tkns (18.59% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities**Date: 2025-03-24Source: {'uri': 'eagletribune.com', 'dataType': 'news', 'title': 'Eagle-Tribune'}URL: https://www.eagletribune.com/region/actinium-pharmaceuticals-announces-supply-agreement-with-eckert-ziegler-for-ac-225-radioisotope-to-support-comprehensive/article_7b70f8f9-c688-590b-8c87-4ca1c8ea4815.htmlNEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product A

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_9 [2025-03-26 09:12:15 -0400] 1088 Bytes | 339 tokens | Cum: 1828 tkns (22.85% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-16T15:53:00Z - Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials
B2 - 2024-10-21T17:00:00Z - Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
B3 - 2024-09-09T08:56:00Z - Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030
B4 - 2024-06-20T13:40:12Z - Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
B5 - 2024-06-04T13:40:10Z - Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
B6 - 2024-01-06T10:58:00Z - The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATNM_OUT_11 [2025-03-26 09:12:20 -0400] 866 Bytes | 227 tokens | Cum: 2057 tkns (25.71% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/10/21/2966426/0/en/Allogeneic-Hematopoietic-Stem-Cell-Transplant-Market-to-Grow-Rapidly-During-the-Study-Period-2020-2034-DelveInsight.htmlThe allogeneic hematopoietic stem cell transplant market is expected to experience significant growth in the coming years, driven by advances in transplantation techniques, improved donor-matching technologies, and a rising incidence of hematological malignancies. Prominent companies working in this domain are actively developing innovative allogeneic HSCT drugs.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_13 [2025-03-26 09:12:22 -0400] 1070 Bytes | 263 tokens | Cum: 2392 tkns (29.90% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S2 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S3 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATNM_OUT_15 [2025-03-26 09:12:23 -0400] 1038 Bytes | 218 tokens | Cum: 2612 tkns (32.65% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I - FINANCIAL INFORMATION

ITEM 1. UNAUDITED FINANCIAL STATEMENTS

The accompanying condensed consolidated financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at September 30, 2024 and December 31, 2023, and the results of operations and cash flows for the three months and nine months ended September 30, 2024 and 2023, respectively, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes th

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_17 [2025-03-26 09:12:35 -0400] 4223 Bytes | 1190 tokens | Cum: 3804 tkns (47.55% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Volume: 4,698,345 | SMA50: 29.78% | Market Cap: 49.29M | Option/Short: Yes / Yes | Sales past 5Y: -27.50% | Sales Surprise: - |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Avg Volume: 314.04K | SMA200: -41.96% | Shs Outstand: 31.20M | Short Float: 7.27% | Employees: 49 | EPS Surprise: -13.18% |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Rel Volume: 19.45 | Perf Week: 32.77% | Shs Float: 30.40M | Short Ratio: 7.04 | Debt/Eq: 0.04 | P/E: - |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| RSI (14): 69.78 | Perf Month: 35.04% | Inst Own: 28.73% | Short Interest: 2.21M | Sales Y/Y TTM: 80.00% | Earnings: Mar 14 |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| ATR (14): 0.15 | Perf Quarter: 41.07% | Insider Own: 2.54% | Beta: -0.19 | ROE: -100.05% | |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| SMA20: 28.82% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -103.95% | |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -11568000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.58
Average Volume: 473526.45
30-Day High: 1.58
30-Day Low: 1.06

[Detailed Financials: Q3 2024]
- Total Assets: $82,114,000.0
- Total Liabilities: $43,906,000.0
- Total Equity: $38,208,000.0
- Current Assets: $79,520,000.0
- Current Liabilities: $7,755,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-7,373,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $89,861,000.0
- Total Liabilities: $46,026,000.0
- Total Equity: $43,835,000.0
- Current Assets: $87,068,000.0
- Current Liabilities: $9,728,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.38

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $1,982,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ATNM_OUT_19 [2025-03-26 09:12:38 -0400] 676 Bytes | 167 tokens | Cum: 4165 tkns (52.06% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ATNM_IN_21 [2025-03-26 09:12:39 -0400] 126 Bytes | 29 tokens | Cum: 4222 tkns (52.78% of 8k)
==========================================================================

====================================
[2025-03-26 06:12:39] # Analysis Completed
Elapsed Time: 34.22 seconds